Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
SHOX-related short stature is a primary bone dysplasia characterized by a height that is 2 standard deviations below the corresponding mean height for a given age, sex and population group, in the absence of obvious skeletal abnormalities and other diseases and with normal developmental milestones. Patients present normal bone age with normal limbs, shortening of the extremities (significantly lower extremities-trunk and sitting height-to-height ratios), normal hGH values, normal karyotype, and Leri-Weill dyschondrosteosis-like radiological signs (e.g. triangularization of distal radial epiphyses, pyramidalization of distal carpal row, and lucency of the distal radius on the ulnar side). Mesomelic disproportions and Madelung deformity are not apparent at a young age, but may develop later in life or never.
Features include: Short stature.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Growth and development | 1 | Short stature |
SHOX function has not been fully characterized.
SHOX-related short stature is associated with mutations in the SHOX gene on chromosome X.
No correlation has been established between the severity of phenotype and the underlying SHOX pathogenic variant [, , , ]. Based on a limited number of studies, the frequency of LWS is greater than SHOX-deficient short stature caused by a SHOX enhancer deletion , suggesting that enhancer deletions cause a more severe phenotype. In the French population, however, deletions of the downstream enhancer region of SHOX appear to be associated with a milder phenotype . Thus, this issue remains unresolved.
The phenotypic spectrum of SHOX deficiency disorders, caused by haploinsufficiency of the short stature homeobox-containing gene (SHOX), ranges from nonspecific short stature with absence of mesomelia and Madelung deformity (called SHOX-deficient short stature in this GeneReview) at the mild end of the spectrum to Leri-Weill dyschondrosteosis (LWD) at the severe end of the spectrum.
SHOX-related Leri-Weill dyschondrosteosis (LWD) should be suspected in individuals with the following clinical and radiographic findings.
No approved treatments are currently available for SHOX-related short stature. The disease remains an area of unmet medical need.
To establish the extent of disease and needs in an individual diagnosed with SHOX deficiency, the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended :
The growth of a child with SHOX deficiency should be monitored every six months. In case of growth failure or short stature, treatment with recombinant human growth hormone is an option to increase growth rate and adult height; consultation with a pediatric endocrinologist is recommended.
Source: GeneReviews — "SHOX Deficiency Disorders"
No clinical trials have been registered for SHOX-related short stature.
31 publications have been identified in PubMed for SHOX-related short stature. Research spans Epidemiology / Natural History (29%), Case Report / Case Series (19%), and Review / Meta-Analysis (16%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 9 | 29% |
Data assembled from 7 of 12 sources · Last updated Sep 18, 2026, 11:51 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about SHOX-related short stature
The phenotypic spectrum of SHOX deficiency disorders ranges from Leri-Weill dyschondrosteosis (LWD) at the severe end of the spectrum to SHOX-deficient short stature (without mesomelia or Madelung deformity) at the mild end. In adults with SHOX deficiency, the proportion of LWD versus SHOX-deficient short stature is not well defined. In LWD the classic clinical triad is short stature, mesomelia, and Madelung deformity. Mesomelia, in which the middle portion of a limb is shortened in relation to the proximal portion, can be evident first in school-aged children and increases with age in frequency and severity. Madelung deformity (abnormal alignment of the radius, ulna, and carpal bones at the wrist) typically develops in mid-to-late childhood and is more common and severe in females.
Source: GeneReviews — "SHOX Deficiency Disorders"
Source: GeneReviews — "SHOX Deficiency Disorders"
While the penetrance of SHOX deficiency is high, its clinical expression is highly variable, becomes more pronounced with age, and is more severe in females. For reasons unknown, the female-to-male ratio in studied cohorts with SHOX deficiency is increased.
Source: GeneReviews — "SHOX Deficiency Disorders"
Short stature is defined as height below the third centile of the reference population. Mesomelia (disproportionate shortening of the middle portion of the limbs) is present in 60%-100% of females and 45%-82% of males with LWD older th...
Source: GeneReviews — "SHOX Deficiency Disorders"
The differential diagnosis of isolated SHOX-deficient short stature includes the following:
Turner syndrome in females (See .)
Children of both sexes with short stature of unknown cause (often called idiopathic short stature [ISS]). ISS is defined as height below the third centile in an individual for whom no skeletal, hormonal, chromosomal, or genetic etiology . With the recent use of methods to detect SHOX deletions/duplications and SHOX enhancer deletions, SHOX-deficient short stature appears to comprise 10% to 20% of children with apparent ISS [, , , , ]. (Using less sensitive molecular genetic testing methods, the prevalence of SHOX-deficient short stature in children who had been identified as having ISS was estimated at 2%-10% [, , , , , , ].)
Source: GeneReviews — "SHOX Deficiency Disorders"
Genetic testing for SHOX is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for SHOX-related short stature has been reported in the published literature.
Assessment of pubertal stage in preadolescents to determine if use of recombinant human growth hormone (rhGH) is appropriate
Madelung deformity. Prominence of distal ulna, limitation of forearm pronation and supination, and wrist pain
• Scoliosis
Body mass index. Frequently above the mean; mainly because of shortening of the legs
Other. Consultation with a clinical geneticist and/or genetic counselor
Treatment of Manifestations
For prepubertal children with short stature, recombinant human growth hormone (rhGH therapy) (dose 50 g/kg body weight/day) should be offered. The therapeutic effect is a gain in final height of 7 to 10 cm. Hand/wrist radiographs for bone age determination should be taken at the initial visit and annually during rhGH therapy to assess maturation tempo. Treatment with high-dose rhGH augments the growth of children with SHOX deficiency to the same extent as in Turner syndrome according to a two-year randomized controlled trial . This effect caused a similar gain in final height as well . No adverse radiologic effects were noted in those who were treated .
Source: GeneReviews — "SHOX Deficiency Disorders"
If Madelung deformity is associated with discomfort, physical activities such as lifting, gripping, writing, typing, and sports that strain the wrist should be limited and ergonomic aids sought .
Source: GeneReviews — "SHOX Deficiency Disorders"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "SHOX Deficiency Disorders"
View trials for SHOX-related short stature
Patient case studies
6 |
19% |
Research summaries | 5 | 16% |
Laboratory research | 5 | 16% |
Testing and diagnosis research | 3 | 10% |
Clinical study results | 2 | 6% |
Other research | 1 | 3% |
Gürlek E (2026). [PMID: 41908539](https://pubmed.ncbi.nlm.nih.gov/41908539/). *Front Pediatr*. [Epidemiology / Natural History]
Beskorovainaya TS (2026). [PMID: 41683999](https://pubmed.ncbi.nlm.nih.gov/41683999/). *Int J Mol Sci*. [Case Report / Case Series]
Rajkumar V (2026). [PMID: 32644549](https://pubmed.ncbi.nlm.nih.gov/32644549/). *Unknown Journal*. [Epidemiology / Natural History]
Shalev-Goldman E (2026). [PMID: 41211650](https://pubmed.ncbi.nlm.nih.gov/41211650/). *Clin Genet*. [Clinical Trial Publication]
Beber SA (2026). [PMID: 41626797](https://pubmed.ncbi.nlm.nih.gov/41626797/). *Spine (Phila Pa 1976)*. [Epidemiology / Natural History]
Aguilar D (2026). [PMID: 30969602](https://pubmed.ncbi.nlm.nih.gov/30969602/). *Unknown Journal*. [Epidemiology / Natural History]
Doğan Arı AB (2026). [PMID: 42230379](https://pubmed.ncbi.nlm.nih.gov/42230379/). *Eur J Pediatr*. [Review / Meta-Analysis]
Zeng Q (2025). [PMID: 40473745](https://pubmed.ncbi.nlm.nih.gov/40473745/). *Sci Rep*. [Epidemiology / Natural History]
Trigui M (2025). [PMID: 40987814](https://pubmed.ncbi.nlm.nih.gov/40987814/). *Eur J Hum Genet*. [Basic Science / Preclinical]
Kohkalani M (2025). [PMID: 41042407](https://pubmed.ncbi.nlm.nih.gov/41042407/). *Mol Biol Rep*. [Basic Science / Preclinical]
AI-curated news mentioning SHOX-related short stature
Updated Sep 1, 2026
A recent study analyzes genetic factors contributing to short stature within a family, providing insights into potential hereditary patterns. This research may inform future genetic testing and treatment approaches for affected individuals.
A study investigates the effectiveness of systematic versus targeted molecular screening for SHOX gene variations in children with idiopathic short stature. The findings could inform genetic testing strategies for this population.